Mr. Rene Goehrum reports

BIOSYENT DECLARES FOURTH QUARTER 2024 DIVIDEND

BioSyent Inc.'s board of directors has declared a quarterly dividend of 4.5 cents per common share, payable in Canadian dollars on Dec. 16, 2024, to shareholders of record at the close of business on Nov. 29, 2024. This fourth quarter 2024 dividend compares with the third quarter 2024 dividend of 4.5 cents per common share. This dividend qualifies as an eligible dividend for Canadian income tax purposes. The declaration, timing, amount and payment of future dividends remain at the discretion of the board of directors.

About BioSyent Inc.

Listed on the TSX Venture Exchange under the trading symbol RX, BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other health care products that have been successfully developed, are safe and effective, and have a proven record of improving the lives of patients. BioSyent supports the health care professionals that treat these patients by marketing its products through its community, specialty and international business units.

As of the date of this news release, the company has 11,594,101 common shares outstanding.

We seek Safe Harbor.